SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazilian election developments and relief over Nu Holdings statement that it is not pursuing a Monzo deal are driving discussion of the rebound. Traders are hopeful the recovery continues, while others doubt the move will hold and frame it as a short squeeze.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is drawing attention for its role in meeting AI data-center power demand, with traders focused on Oracles reaffirmed Project Jupiter fuel-cell commitment and Blooms ability to scale onsite power deployments. Bulls see strong demand and growth potential, while skeptics cite execution risks around the project, high valuation, and sharp share-price swings.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus ARCT-810 Phase 2 update, including encouraging OTC-deficiency findings and the introduction of its LUNAR 2.0 delivery platform, is driving discussion; traders also point to the myNEO acquisition as a potential boost to drug discovery. Reactions are mixed: some view the data and platform update as long-term progress, while others say the announcement fell short of a major breakthrough and worry about added costs and delayed timelines.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Sam Altmans description of Cerebras as a close OpenAI partner is fueling a bullish rebound narrative after a report that OpenAIs latest Ultrafast mode used Nvidia GPUs raised doubts about the relationship. Traders are celebrating Altmans comments and anticipating a short squeeze, while others warn that insider share unlocks and selling could continue to weigh on the stock.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital shares sold off sharply after reports that Toshiba plans to expand hard-drive capacity for AI data centers, raising concerns about future competition, supply, and pricing power. Traders are divided between viewing the reaction as an overreaction because the ramp would take time and seeing it as a threat to margins, while many are buying the dip and others remain cautious about continued weakness.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys QNX momentum is driving attention, especially a record Alloy Kore design win for the Coretura vehicle platform, a newly disclosed Uber design win, and stronger results with raised guidance. Many traders see these developments as evidence of growth in software-defined vehicles and physical AI, while others question how quickly the wins will translate into revenue and have debated the stocks volatile, sometimes muted reaction.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Reports of a planned federal loan to upgrade Vistras nuclear plants are driving attention, with traders linking the expansion to rising AI and data-center electricity demand. Many see the plan as bullish, while others note it remains unfinalized and complain that sharp, choppy trading has muted the response.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is drawing attention amid a broader crypto and meme-coin bounce, with traders citing bullish chart signals and a reclaim of a long-term moving average. The mood is optimistic about a breakout, but others see DOGE as stagnant and note that it continues to struggle at psychological resistance.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

A weak U.S. jobs report eased rate-hike concerns and pulled Treasury yields lower, prompting a rebound in rate-sensitive small caps. Traders are debating whether the move off IWMs 200-day moving average marks a durable recovery or a brief bounce after prolonged underperformance versus mega-cap tech.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is drawing attention for choppy, low-volume trading around a stubborn resistance zone, with traders split between expecting a breakout or short squeeze and seeing continued range-bound price action. Bulls cite possible peptide/GLP-1 expansion and upcoming earnings, while skeptics point to legal overhangs and weak momentum; these potential catalysts remain speculative in the discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Equity

Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year.


OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.

Ocugen (OCGN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?

Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.

OCGN's Catalyst Calendar for Trial Data and Filings Through 2028

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.

This account has been verified as an official OCGN representative.

Verified Account

Ocugen

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Ocugen Inc

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be this week?

Current Price	$1.02
Prev Close	$1.00
Open	$1.04
Dividend Yield	0.00%
50-Day Moving Average	$1.22
Beta	1.52
Avg. Volume	8.88M
PE Ratio	-4.01

52-Week High	$2.73
52-Week Low	$0.97
Market Capitalization	$345.89M
EPS (Annual)	-$0.226
Price to Book	-20.89
Revenue Per Employee	$38,043.10

Feed

News

Sentiment

Earnings

Fundamentals

Info

OCGN Fundamentals